Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MVD | P53602 | 3/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 3/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23351231 | 1.00 | FDPS (0.50) | FDPSBLMTDP1BTN3A1CA2 | |
| SCHEMBL11911193 | 0.97 | FDPS (0.47) | FDPSBLMTDP1BTN3A1CA2 | |
| SCHEMBL10062709 | 0.91 | CA2 (0.47) | FDPSBLMTDP1BTN3A1CA2 | |
| SCHEMBL14870920 | 0.84 | — | — | |
| SCHEMBL2045368 | 0.84 | — | — | |
| SCHEMBL16286118 | 0.84 | — | — | |
| Triphosphate SCHEMBL18714 | 0.84 | FDPS (0.69) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL15555988 | 0.84 | FDPS (0.69) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL13321387 | 0.82 | FDPS (0.50) | FDPSBLMTDP1BTN3A1CA2 | |
| Triphosphate SCHEMBL28345672 | 0.81 | FDPS (0.56) | FDPSBLMTDP1BTN3A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310481-A1 | BI- AND MONOCYCLIC NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | Janssen Pharmaceuticals, Inc. | 2023-10-05 | — | — | US | disclosed |
| US-20230310481-A1 | BI- AND MONOCYCLIC NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | Janssen Pharmaceuticals, Inc. | 2023-10-05 | — | — | US | disclosed |
| EP-3512486-B2 | BLUE POWDER AND USE THEREOF IN COSMETICS | OREAL (FR) | 2023-07-12 | — | — | EP | disclosed |
| US-20230201207-A1 | COMBINATION CANCER THERAPY USING N2-QUINOLINE OR ISOQUINOLINE SUBSTITUTED PURINE DERIVATIVES | Shanghai Huayu Biotechnology Co., Ltd. (CN) | 2023-06-29 | — | — | US | disclosed |
| WO-2023109775-A1 | PYRIMIDINE-ANNULATED TRIAZOLE DERIVATIVES AND THEIR USE IN PLATELET AGGREGATION INHIBITION | BEIJING HONGHUI MEDITECH CO., LTD (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023108363-A1 | PYRIMIDINE-ANNULATED TRIAZOLE DERIVATIVES AND THEIR USE IN PLATELET AGGREGATION INHIBITION | BEIJING HONGHUI MEDITECH CO., LTD (CN) | 2023-06-22 | — | — | WO | disclosed |
| US-20230151048-A1 | CRYSTAL FORM, PREPARATION METHOD, AND APPLICATION OF 4′-SUBSTITUTED NUCLEOSIDE | HENAN GENUINE BIOTECH CO., LTD. (CN) | 2023-05-18 | — | — | US | disclosed |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-09-23 | — | — | US | disclosed |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-08-05 | — | — | US | disclosed |
| US-20210139524-A1 | SPIROTHIETANE NUCLEOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
| CN-100384865-C | Methods and compositions for therapeutic use of RNA interference | INSERT THERAPEUTICS INC (US) | 2008-04-30 | — | — | CN | disclosed |
| CN-101072874-A | Aptamer-regulated nucleic acids and uses thereof | CALIFORNIA INST OF TECHN (US) | 2007-11-14 | — | — | CN | disclosed |
| US-7282581-B2 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | WALLAC OY (FI) | 2007-10-16 | — | — | US | disclosed |
| US-20070219361-A1 | Synthesis and compositions of nucleic acids comprising 2'-terminator nucleotides | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007095269-A2 | NUCLEOSIDE ARYL PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK & CO., INC. (US) | 2007-08-23 | — | — | WO | disclosed |
| CN-101018541-A | Controlled and sustained delivery of nucleic acid-based therapeutic agents | CONTROL DELIVERY SYS INC (US) | 2007-08-15 | — | — | CN | disclosed |
| CN-1984672-A | Modulation of NKG2D | UNIV CALIFORNIA (US) | 2007-06-20 | — | — | CN | disclosed |
| WO-2007021610-A2 | RIBONUCLEOSIDE CYCLIC ACETAL DERIVATIVES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| CN-1917897-A | Composition and methods for modulating cns activity | CURIS INC (US) | 2007-02-21 | — | — | CN | disclosed |
| CN-1771255-A | Methods and compositions for therapeutic use of RNA interference | INSERT THERAPEUTICS INC (US) | 2006-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310481-A1 | BI- AND MONOCYCLIC NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | NME2, HAVCR2, NME1 | FDPS 614/4885BLM 104/4885TDP1 1592/4885 |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | IAPP, SLC5A2, SLC2A2 | FDPS 4651/4885BLM 3549/4885TDP1 3903/4885 |
| US-20070219361-A1 | Synthesis and compositions of nucleic acids comprising 2'-terminator nucleotides | RNGTT, POLRMT, NT5C3B | FDPS 567/4885BLM 320/4885TDP1 238/4885 |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | FDPS 1328/4885BLM 1207/4885TDP1 1557/4885 |
| US-20230201207-A1 | COMBINATION CANCER THERAPY USING N2-QUINOLINE OR ISOQUINOLINE SUBSTITUTED PURINE DERIVATIVES | NME2, NTPCR, TYMP | FDPS 2712/4885BLM 479/4885TDP1 794/4885 |
| US-20210139524-A1 | SPIROTHIETANE NUCLEOSIDES | SAMHD1, SLC28A1, SLC28A2 | FDPS 113/4885BLM 3615/4885TDP1 1189/4885 |
| US-20230151048-A1 | CRYSTAL FORM, PREPARATION METHOD, AND APPLICATION OF 4′-SUBSTITUTED NUCLEOSIDE | PNP, CCR5, CD4 | FDPS 1265/4885BLM 2774/4885TDP1 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.